Global Artificial Intelligence (AI) In Pharmacovigilance Market To Expand At 19.6% CAGR During The Forecast Period

The Business Research Company's Global Artificial Intelligence (AI) In Pharmacovigilance Market To Expand At 19.6% CAGR During The Forecast Period



The Business Research Company

LONDON, GREATER LONDON, UNITED KINGDOM, September 3, 2026 /EINPresswire.com/ -- "The integration of artificial intelligence (AI) into pharmacovigilance is transforming drug safety monitoring, enabling more efficient and accurate detection of adverse reactions. This rapidly evolving market is drawing significant attention due to technological advancements and increasing regulatory demands. Below is a detailed overview of the current market size, growth factors, leading regions, and trends shaping the future of AI in pharmacovigilance.

> Expected to grow to $1.88 billion in 2030 at a compound annual growth rate (CAGR) of 19.6%”
>
> *The Business Research Company*

Current Market Size and Future Growth Trajectory of AI in Pharmacovigilance

The AI in pharmacovigilance market has witnessed swift expansion recently. It is projected to increase from $0.77 billion in 2025 to $0.92 billion in 2026, growing at a compound annual growth rate (CAGR) of 19.3%. This upward trend during the past years has been driven by a rise in global adverse drug reaction reporting requirements, broader pharmacovigilance regulatory frameworks, greater adoption of electronic health records, increasing complexity in clinical trial data, and the initial use of rule-based drug safety monitoring systems.

Download a free sample of the artificial intelligence (ai) in pharmacovigilance market report: https://thebusinessresearchcompany.com/sample_request?id=70195181&type=smp&name=Artificial%20Intelligence%20%28AI%29%20In%20Pharmacovigilance%20Market%20Report%202026&utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Sep_PR

Looking ahead, the market is expected to experience even more robust growth. By 2030, it is

anticipated to reach $1.88 billion, expanding at a CAGR of 19.6%. This acceleration stems from the swift adoption of AI-powered drug safety surveillance systems, the growing volume of real-world healthcare data available for analysis, tightening regulatory compliance standards, enhanced use of predictive analytics to identify adverse events, and the integration of multi-source clinical data for pharmacovigilance purposes. Prominent trends in this period include the rise of automated literature screening for detecting adverse drug reactions, increasing use of real-world evidence analytics in drug safety, the growing role of generative AI in regulatory reporting, expansion of automated case intake and workflow processing, and heightened cross-border regulatory harmonization for data exchange.

Understanding AI's Role in Pharmacovigilance Processes
Artificial intelligence in pharmacovigilance applies technologies such as machine learning, natural language processing, and advanced data analytics to identify, assess, monitor, and prevent adverse drug reactions and other safety concerns. AI streamlines drug safety surveillance by automating the analysis of massive amounts of both structured and unstructured healthcare data. This automation allows for quicker detection of safety signals, more precise risk assessments, and improved regulatory reporting. Consequently, AI supports better decision-making in drug safety management by minimizing manual labor and enhancing the reliability of safety insights.

View the full artificial intelligence (ai) in pharmacovigilance market report:
https://www.thebusinessresearchcompany.com/report/artificial-intelligence-ai-in-pharmacovigilance-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Sep_PR

Primary Factors Driving Growth in the AI in Pharmacovigilance Market
One of the key growth drivers for this market is the increasing volume of adverse event (AE) reports. These reports document unintended or harmful reactions following the use of medical products or drugs. The surge in AE reports is largely due to stricter regulatory mandates requiring healthcare providers and pharmaceutical companies to report a broader range of safety issues more frequently and with greater detail. AI technology plays a crucial role by automatically gathering and analyzing vast amounts of safety data from multiple sources in real-time. This capability enables faster identification of drug safety signals and improves accuracy and consistency in reporting and compliance with regulations.

For instance, in February 2024, the Department of Health Abu Dhabi published the Analysis of Adverse Drug Reactions 2023 Report, revealing that 1,522 adverse drug reaction reports were submitted to their pharmacovigilance program between January and December 2023. This figure represents a 235% increase compared to the average annual reports in previous years, underscoring how rising AE volumes are propelling the demand for AI-driven pharmacovigilance solutions.

Regional Outlook and Growth Forecast for AI in Pharmacovigilance

North America held the largest share of the AI in pharmacovigilance market in 2025, reflecting its advanced healthcare infrastructure and early adoption of AI technologies. Meanwhile, the Asia-Pacific region is projected to be the fastest-growing market during the forecast period, supported by increasing healthcare digitization, expanding pharmaceutical industries, and rising regulatory focus on drug safety. The market analysis includes key regions such as Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, providing a comprehensive global perspective on evolving market dynamics.

What's new in our 2026 market reports:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel dashboards
• Market hotspots infographics
• Key technologies and future trends
• Updated graphics and tables

Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: marketing@tbrc.info

The Business Research Company - www.thebusinessresearchcompany.com

Follow Us On:
• LinkedIn: https://in.linkedin.com/company/the-business-research-company"

Oliver Guirdham
The Business Research Company
+44 7882 955267
info@tbrc.info
Visit us on social media:
LinkedIn
Facebook
X

This press release can be viewed online at: https://www.einpresswire.com/article/939345771

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire,

Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.
© 1995-2026 Newsmatics Inc. All Right Reserved.